REG-argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
argenx reported Q3 2026 VYVGART global product net sales of $1.7 billion, up 54% year-over-year and 13% quarter-over-quarter, with quarterly profit of $506 million and basic EPS of $8.07. On the pipeline, the company reported positive Phase 3 ALKIVIA results in IMNM and dermatomyositis, submitted an sBLA in ocular myasthenia gravis, and confirmed the VYVGART Hytrulo IMNM sBLA is on track for year-end submission; empasiprubart Phase 3 MMN topline data are expected in December 2026 and FB102 is advancing to Phase 3 in celiac disease.
Key figures
- Eps
- 8.07
- Revenue
- 1721000000
- Guidance
- Combined R&D and SG&A expenses of approximately $4 billion for 2026, including Forte transaction-related costs
- Revenue Yoy
- 54%
- Profit q3
- 506000000
- Revenue qoq
- 13%
- Eps basic q3
- 8.07
- Eps diluted q3
- 7.8
- Profit nine months
- 1344000000
- Operating profit q3
- 486000000
- Total operating income q3
- 1751000000
- Forte acquisition cash cost
- 2100000000
- Forte acquisition expense q3
- 150000000
- Product net sales nine months
- 4534000000
- Cash and current financial assets
- 3700000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.